The European medicines regulatory network needs to up its game in the area of data analysis and digital health so that it can keep up with new developments in technology and “get at least on a par with the pharmaceutical industry, if not ahead,” says Thomas Senderovitz, director general of the Danish medicines agency.
“Regulators can’t be a bottleneck. This is not acceptable when it comes to new technology, because this will have a negative impact on patients if we can’t… evaluate new medicines...